Literature DB >> 16613920

Short term oral minocycline treatment of meibomianitis.

J D Aronowicz1, W E Shine, D Oral, J M Vargas, J P McCulley.   

Abstract

AIM: To evaluate the clinical impact, aqueous tear parameters, and meibomian gland morphology in patients with primary meibomianitis before, during, and 3 months after a course of oral minocycline.
METHODS: 16 patients were prospectively enrolled, 11 male and five female (mean age 69 years old). Each patient received routine clinical evaluations before, after 3 months therapy, and at 6 month study follow up visit. The clinical appearance, tear volume, flow and turnover, evaporation, Schirmer I test, meibomian gland dropout, lissamine green staining, and bacteriology wer evaluated.
RESULTS: Improvement was observed in clinical signs of meibomianitis at the second and third visits. Microbial culture findings improved. Decreased aqueous tear volume and flow, and increased evaporation rate range at 35-45% relative humidity (RH) (p < 0.05) were also detected. Other related tear parameters did not change. Meibomian gland dropout showed no improvement.
CONCLUSIONS: 3 months of oral minocycline resulted in clinical improvements in all meibomianitis signs that persisted for at least 3 months after discontinuation despite decreased aqueous tear volume and flow with increased evaporation (35-45% RH). However, there was improvement in the turbidity of secretions. Short term minocycline therapy probably has efficacy in the management of meibomianitis that extends beyond eradication of bacteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613920      PMCID: PMC1857131          DOI: 10.1136/bjo.2006.091579

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

1.  Model for ocular tear film function.

Authors:  W D Mathers; J A Lane; J E Sutphin; M B Zimmerman
Journal:  Cornea       Date:  1996-03       Impact factor: 2.651

2.  Diagnostic tests in the Sicca syndrome.

Authors:  O P van Bijsterveld
Journal:  Arch Ophthalmol       Date:  1969-07

3.  A new technique for tear film fluorophotometry.

Authors:  N Eter; M Göbbels
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

4.  Challenges and pitfalls in clinical trials of treatments for dry eye.

Authors:  Gary N Foulks
Journal:  Ocul Surf       Date:  2003-01       Impact factor: 5.033

5.  Presumed hyposecretory/hyperevaporative KCS: tear characteristics.

Authors:  James P McCulley; Ward E Shine; Joel Aronowicz; Deniz Oral; Jose Vargas
Journal:  Trans Am Ophthalmol Soc       Date:  2003

6.  Entry of four tetracyclines into saliva and tears.

Authors:  P D Hoeprich; D M Warshauer
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

7.  Hamster flank organ hydrolase and lipase activity.

Authors:  A Gulbenkian; J Myers; D Fries
Journal:  J Invest Dermatol       Date:  1980-10       Impact factor: 8.551

8.  Measurement of basal tear turnover using a standardized protocol. European concerted action on ocular fluorometry.

Authors:  J A van Best; J M Benitez del Castillo; L M Coulangeon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-01       Impact factor: 3.117

9.  Minocycline effect on meibomian gland lipids in meibomianitis patients.

Authors:  W E Shine; J P McCulley; A G Pandya
Journal:  Exp Eye Res       Date:  2003-04       Impact factor: 3.467

10.  Classification of chronic blepharitis.

Authors:  J P McCulley; J M Dougherty; D G Deneau
Journal:  Ophthalmology       Date:  1982-10       Impact factor: 12.079

View more
  17 in total

Review 1.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy.

Authors:  Yukihiro Matsumoto; Yuta Shigeno; Enrique Adan Sato; Osama M A Ibrahim; Megumi Saiki; Kazuno Negishi; Yoko Ogawa; Murat Dogru; Kazuo Tsubota
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-20       Impact factor: 3.117

Review 3.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.

Authors:  Gerd Geerling; Joseph Tauber; Christophe Baudouin; Eiki Goto; Yukihiro Matsumoto; Terrence O'Brien; Maurizio Rolando; Kazuo Tsubota; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 4.  The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland.

Authors:  Erich Knop; Nadja Knop; Thomas Millar; Hiroto Obata; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 5.  Therapeutic Strategies to Treat Dry Eye in an Aging Population.

Authors:  Nisreen S Ezuddin; Karam A Alawa; Anat Galor
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

Review 6.  [Diagnosis and treatment of the watering eye].

Authors:  M Schargus; G Geerling
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

Review 7.  Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD).

Authors:  Adam R Thode; Robert A Latkany
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 8.  Dry eye disease and microbial keratitis: is there a connection?

Authors:  Srihari Narayanan; Rachel L Redfern; William L Miller; Kelly K Nichols; Alison M McDermott
Journal:  Ocul Surf       Date:  2013-01-29       Impact factor: 5.033

9.  [Meibomian glands : part III. Dysfunction - argument for a discrete disease entity and as an important cause of dry eye].

Authors:  E Knop; N Knop; H Brewitt; U Pleyer; P Rieck; B Seitz; F Schirra
Journal:  Ophthalmologe       Date:  2009-11       Impact factor: 1.059

Review 10.  [The "wet" dry eye].

Authors:  M Schargus; G Geerling
Journal:  Ophthalmologe       Date:  2009-03       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.